Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (91-100 of 220) with videos related to

Pageof 22
Sort By:
Clinical Lung Cancer|February 4, 2014
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Filippo de Marinis, Federico Cappuzzo, et al.
Clinical Colorectal Cancer|August 16, 2011
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancerDavid R Spigel, Johanna C Bendell, Michael McCleod, et al.
Clinical Lung Cancer|February 25, 2014
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerJoachim von Pawel, Jimmie H Harvey, David R Spigel, et al.
Clinical Breast Cancer|November 26, 2009
A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancerDenise A Yardley, Howard A Burris, David R Spigel, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2012
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, Mark S Rubin, et al.
Cancer Investigation|July 6, 2016
A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal TumorsJohanna C Bendell, Todd M Bauer, Ruth Lamar, et al.
Pigment Cell & Melanoma Research|July 16, 2015
A phase II trial of erlotinib and bevacizumab for patients with metastatic melanomaTejaswi V Mudigonda, Kenneth Wyman, David R Spigel, et al.
Breast Cancer Research and Treatment|November 29, 2023
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancerErica L Mayer, Nabihah Tayob, Siyang Ren, et al.
Clinical Genitourinary Cancer|February 15, 2008
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trialJohn D Hainsworth, David R Spigel, Jeffrey A Sosman, et al.
Cancer Biology & Therapy|January 30, 2013
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trialJeffrey R Infante, Hendrik-Tobias Arkenau, Johanna C Bendell, et al.
Pageof 22

Showing results (91-100 of 220) with videos related to

Sort By:
Pageof 22
Clinical Lung Cancer|February 4, 2014
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Filippo de Marinis, Federico Cappuzzo, et al.
Clinical Colorectal Cancer|August 16, 2011
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancerDavid R Spigel, Johanna C Bendell, Michael McCleod, et al.
Clinical Lung Cancer|February 25, 2014
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerJoachim von Pawel, Jimmie H Harvey, David R Spigel, et al.
Clinical Breast Cancer|November 26, 2009
A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancerDenise A Yardley, Howard A Burris, David R Spigel, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2012
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, Mark S Rubin, et al.
Cancer Investigation|July 6, 2016
A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal TumorsJohanna C Bendell, Todd M Bauer, Ruth Lamar, et al.
Pigment Cell & Melanoma Research|July 16, 2015
A phase II trial of erlotinib and bevacizumab for patients with metastatic melanomaTejaswi V Mudigonda, Kenneth Wyman, David R Spigel, et al.
Breast Cancer Research and Treatment|November 29, 2023
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancerErica L Mayer, Nabihah Tayob, Siyang Ren, et al.
Clinical Genitourinary Cancer|February 15, 2008
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trialJohn D Hainsworth, David R Spigel, Jeffrey A Sosman, et al.
Cancer Biology & Therapy|January 30, 2013
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trialJeffrey R Infante, Hendrik-Tobias Arkenau, Johanna C Bendell, et al.
Pageof 22